Pediatric Growth Hormone Deficiency Clinical Trial
Official title:
Post Marketing Surveillance (PMS) Study for Ngenla Prefilled Pen in Pediatric Patients Who Have Endogenous Growth Failure Due to an Inadequate Secretion of Endogenous Growth Hormone in Korea
This non-interventional study will be performed by design of post-marketing surveillance (PMS) as an additional pharmacovigilance activity of the Risk Management Plan (RMP) for Ngenla® pre-filled pen injection, which is required by the Ministry of Food and Drug Safety (MFDS) according to the local regulation. This post-marketing surveillance will investigate the safety and effectiveness of Ngenla® pre-filled pen injection as the treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone during 6 years under the setting of routine practice in Korea.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01718041 -
Versartis Trial in Children to Assess Long-Acting Growth Hormone
|
Phase 1/Phase 2 | |
| Terminated |
NCT02068521 -
Versartis Long-Term Safety Study of Somavaratan
|
Phase 2/Phase 3 | |
| Completed |
NCT04633057 -
A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency
|
Phase 3 | |
| Withdrawn |
NCT06113952 -
A Study to Compare the Experiences of Taking Daily Growth Hormone Injections to Weekly Ngenla in Children With Low Levels of Growth Hormone
|
||
| Completed |
NCT01592500 -
Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
|
Phase 2 | |
| Active, not recruiting |
NCT02968004 -
Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
|
Phase 3 | |
| Terminated |
NCT02413138 -
Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)
|
Phase 2/Phase 3 |